[Comment] Is there any interest in a new BRAF –MEK inhibitor combination in melanoma?

BRAF –MEK inhibitor combinations are still the backbone of treatment for BRAF-mutant metastatic melanoma, despite the increasing role of anti-PD1 inhibitors. In the past 4 years, three trials1–3 in BRAF-mutated metastatic melanoma have shown the superiority of the combination of BRAF and MEK inhibito rs over BRAF inhibitors alone, with better efficacy and lower toxicity—namely, the superiority of dabrafenib–trametinib over monotherapy with dabrafenib or vemurafenib, and the superiority of vemurafenib–cobimetinib over monotherapy with vemurafenib.

Source: The Lancet Oncology - March 22, 2018 Category: Cancer & Oncology Authors: Jean Jacques Grob Tags: Comment Source Type: research